Therefore, we assessed the cost-effectiveness of TLE-CHM as a first-line treatment for HER2-negative advanced G/GEJ adenocarcinoma compared to chemotherapy alone from the perspective of the Chinese healthcare system. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.